Kodiak Sciences (NASDAQ:KOD) Posts Earnings Results, Beats Estimates By $0.06 EPS
Kodiak Sciences (NASDAQ:KOD) reported quarterly earnings of ($0.84) per share, surpassing analysts' expectations of ($0.87) by $0.03. The stock opened at $3.06, with a market cap of $161.03 million. Jefferies Financial Group upgraded Kodiak Sciences from "hold" to "buy" with a target price of $20.00. The company focuses on developing therapeutics for retinal diseases, with its lead product candidate in advanced clinical studies.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.
Get Kodiak Sciences alerts:
Kodiak Sciences Stock Performance
NASDAQ:KOD opened at $3.06 on Friday. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $5.40. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60. The company has a market cap of $161.03 million, a PE ratio of -0.84 and a beta of 2.26.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Monday, December 9th.
Read Our Latest Stock Report on KOD
Kodiak Sciences Company Profile
(Get Free Report)Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
- Five stocks we like better than Kodiak Sciences
- What Are Dividends? Buy the Best Dividend Stocks
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- What is Short Interest? How to Use It
- Top 3 Beverage Stocks Pouring Out Profits
- Utilities Stocks Explained – How and Why to Invest in Utilities
- CarMax and Carvana: Steering the Used Car Market
Should You Invest $1,000 in Kodiak Sciences Right Now?
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
